Lv431
572 积分 2026-05-15 加入
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
2天前
已完结
Global consensus statement on the management of pregnancy in inflammatory bowel disease
2天前
已关闭
Real-world effectiveness and safety of risankizumab induction and maintenance therapy in pediatric patients with Crohn’s disease: a multicenter retrospective analysis
3天前
已完结
The Clinical Response of Upadacitinib and Risankizumab Is Associated With Reduced Inflammatory Bowel Disease Anti-TNF-α Inadequate Response Mechanisms
3天前
已完结
Comparative effectiveness and safety of upadacitinib versus vedolizumab in anti-TNF-exposed patients with ulcerative colitis
4天前
已完结
Comparing real-world continuous clinical remission rates of anti-tumor necrosis factor, vedolizumab, ustekinumab, tofacitinib, and upadacitinib in ulcerative colitis
7天前
已完结
Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial
8天前
已完结
The pattern and outcome of acute severe colitis
10天前
已完结
Outcomes of Risankizumab in Patients with Crohn’s Disease and Prior Ustekinumab Exposure in a Multicenter Academic Institution
11天前
已完结
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases
15天前
已完结